Antivirulence drugs to target bacterial secretion systems

Current Opinion in Microbiology

Volumn 13, Issue 1, 2010, Pages 100-105

  Baron, Christian ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANILINE DERIVATIVE; ANTIBIOTIC AGENT; ANTIVIRULENCE AGENT; HYDRAZIDE DERIVATIVE; HYDRAZONE DERIVATIVE; SALICYLALDEHYDE; UNCLASSIFIED DRUG; VIRSTATIN;

ANTIBIOTIC RESISTANCE; BACTERIAL PHENOMENA AND FUNCTIONS; BACTERIAL SECRETION SYSTEM; BACTERIAL VIRULENCE; CHOLERA; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; NONHUMAN; PROTEIN FUNCTION; REVIEW; TYPE II SECRETION SYSTEM; TYPE III SECRETION SYSTEM; TYPE IV SECRETION SYSTEM;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; GRAM-NEGATIVE BACTERIA; HUMANS; MEMBRANE TRANSPORT PROTEINS;

BACTERIA (MICROORGANISMS); NEGIBACTERIA;

EID: 75249090304     PISSN: 13695274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mib.2009.12.003     Document Type: Review

References (33)

1. Levy S.B., and Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 10 (2004) S122-129
2. Clatworthy A.E., Pierson E., and Hung D.T. Targeting virulence: a new paradigm for antimicrobial therapy. Nat Chem Biol 3 (2007) 541-548
3. Walsh C. Antibiotics: Actions, Origins, Resistance (2003), ASM Press, Washington
4. D'Costa V.M., McGrann K.M., Hughes D.W., and Wright G.D. Sampling the antibiotic resistome. Science 311 (2006) 374-377. Sampling of nonpathogenic Streptomyces species from the environment identified resistance genes against all major classes of antibiotics. This publication underlines the very widespread occurrence of antibiotic resistance genes in the environment.
5. Martínez J.L. Antibiotics and antibiotic resistance genes in natural environments. Science 321 (2008) 365-367
6. Abraham E.P., and Chain E. An enzyme from bacteria able to destroy penicillin. Nature 146 (1940) 837
7. Projan S.J., and Bradford P.A. Late stage antibacterial drugs in the clinical pipeline. Curr Opin Microbiol 10 (2007) 441-446
8. Walsh C. Where will new antibiotics come from?. Nat Rev Microbiol 1 (2003) 65-70
9. Baron C., and Coombes B. Targeting bacterial secretion systems: benefits of disarmament in the microcosm. Infect Disord Drug Targets 7 (2007) 19-27
10. Alksne L.E. Virulence as a target for antimicrobial chemotherapy. Expert Opin Investig Drugs 11 (2002) 1149-1159
11. Waksman G., and Hultgren S.J. Structural biology of the chaperone-usher pathway of pilus biogenesis. Nat Rev Microbiol 7 (2009) 765-774
12. Mota L.J., and Cornelis G.R. The bacterial injection kit: type III secretion systems. Ann Med 37 (2005) 234-249
13. Moraes T.F., Spreter T., and Strynadka N.C. Piecing together the type III injectisome of bacterial pathogens. Curr Opin Struct Biol 18 (2008) 258-266
14. Kauppi A.M., Nordfelth R., Uvell H., Wolf-Watz H., and Elofsson M. Targeting bacterial virulence: inhibitors of type III secretion in Yersinia. Chem Biol 10 (2003) 241-249
15. Allaoui A., Schulte R., and Cornelis G.R. Mutational analysis of the Yersinia enterocolitica virC operon: characterization of yscE, F, G, I, J, K required for Yop secretion and yscH encoding YopR. Mol Microbiol 18 (1995) 343-355
16. Gauthier A., Robertson M.L., Lowden M., Ibarra J.A., Puente J.L., and Finlay B.B. Transcriptional inhibitor of virulence factors in enteropathogenic Escherichia coli. Antimicrob Agents Chemother 49 (2005) 4101-4109
17. Nordfelth R., Kauppi A.M., Norberg H.A., Wolf-Watz H., and Elofsson M. Small-molecule inhibitors specifically targeting type III secretion. Infect Immun 73 (2005) 3104-3114
18. Negrea A., Bjur E., Ygberg S.E., Elofsson M., Wolf-Watz H., and Rhen M. Salicylidene acylhydrazides that affect type III protein secretion in Salmonella enterica serovar typhimurium. Antimicrob Agents Chemother 51 (2007) 2867-2876
19. Muschiol S., Bailey L., Gylfe A., Sundin C., Hultenby K., Bergstrom S., Elofsson M., Wolf-Watz H., Normark S., and Henriques-Normark B. A small-molecule inhibitor of type III secretion inhibits different stages of the infectious cycle of Chlamydia trachomatis. Proc Natl Acad Sci U S A 103 (2006) 14566-14571. One of the salicylidene acylhydrazides identified in Yersinia was shown to inhibit the intracellular replication of Chlamydia trachomatis. This publication underlines the broad spectrum of this class of T3SS inhibitors and shows their application for research on the biology of an obligate intracellular pathogen.
20. Veenendaal A.K., Sundin C., and Blocker A.J. Small-molecule type III secretion system inhibitors block assembly of the Shigella type III secreton. J Bacteriol 191 (2009) 563-570
21. Tree J.J., Wang D., McInally C., Mahajan A., Layton A., Houghton I., Elofsson M., Stevens M.P., Gally D.L., and Roe A.J. Characterization of the effects of salicylidene acylhydrazide compounds on type III secretion in Escherichia coli O157:H7. Infect Immun 77 (2009) 4209-4220. Using DNA microarrays the transcriptional response to salicylidene acylhydrazide inhibitors was analyzed showing that many virulence genes are affected in Escherichia coli O157:H7. This publication constitutes an important advance toward understanding the molecular basis of action of these inhibitors.
22. Keyser P., Elofsson M., Rosell S., and Wolf-Watz H. Virulence blockers as alternatives to antibiotics: type III secretion inhibitors against Gram-negative bacteria. J Intern Med 264 (2008) 17-29
23. Felise H.B., Nguyen H.V., Pfuetzner R.A., Barry K.C., Jackson S.R., Blanc M.P., Bronstein P.A., Kline T., and Miller S.I. An inhibitor of Gram-negative bacterial virulence protein secretion. Cell Host Microbe 4 (2008) 325-336. Using an in vivo screen in Salmonella, small molecules were identified that are active against many pathogens and that inhibit type III and type II secretion systems. This publication shows the isolation of molecules with potential for development as broad-spectrum antivirulence drugs.
24. Christie P.J., Atmakuri K., Krishnamoorthy V., Jakubowski S., and Cascales E. Biogenesis architecture, and function of bacterial type IV secretion systems. Annu Rev Microbiol 59 (2005) 451-485
25. Paschos A., Patey G., Sivanesan D., Gao C., Bayliss R., Waksman G., O'Callaghan D., and Baron C. Dimerization and interactions of Brucella suis VirB8 with VirB4 and VirB10 are required for its biological activity. Proc Natl Acad Sci U S A 103 (2006) 7252-7257
26. Terradot L., Bayliss R., Oomen C., Leonard G., Baron C., and Waksman G. Crystal structures of the periplasmic domains of two core subunits of the bacterial type IV secretion system, VirB8 from Brucella suis and ComB10 from Helicobacter pylori. Proc Natl Acad Sci U S A 102 (2005) 4596-4601
27. Hilleringmann M., Pansegrau W., Doyle M., Kaufman S., MacKichan M.L., Gianfaldoni C., Ruggiero P., and Covacci A. Inhibitors of Helicobacter pylori ATPase Cagalpha block CagA transport and cag virulence. Microbiology 152 (2006) 2919-2930
28. Fernandez-Lopez R., Machon C., Longshaw C.M., Martin S., Molin S., Zechner E.L., Espinosa M., Lanka E., and de la Cruz F. Unsaturated fatty acids are inhibitors of bacterial conjugation. Microbiology 151 (2005) 3517-3526
29. Johnson T.L., Abendroth J., Hol W.G., and Sandkvist M. Type II secretion: from structure to function. FEMS Microbiol Lett 255 (2006) 175-186
30. Hung D.T., Shakhnovich E.A., Pierson E., and Mekalanos J.J. Small-molecule inhibitor of Vibrio cholerae virulence and intestinal colonization. Science 310 (2005) 670-674
31. Fronzes R., Christie P.J., and Waksman G. The structural biology of type IV secretion systems. Nat Rev Microbiol 7 (2009) 703-714
32. Simeone R., Bottai D., and Brosch R. ESX/type VII secretion systems and their role in host-pathogen interaction. Curr Opin Microbiol 12 (2009) 4-10
33. Projan S.J. Why is big Pharma getting out of antibacterial drug discovery?. Curr Opin Microbiol 6 (2003) 427-430